1. Anti-tuberculosis and Cytotoxic Evaluation of the Seaweed Sargassum boveanum. Akbari, V., S. Zafari, and A. Yegdaneh. Research in Pharmaceutical Sciences, 2018. 13(1): p. 30-37. PMID[29387109]. PMCID[PMC5772079].
[PubMed]. TB_02_2018.
2. Design, Synthesis of Novel Oxazolidino-amides/sulfonamides Conjugates and Their Impact on Antibacterial Activity. Bharath, Y., G.R. Alugubelli, R. Sreenivasulu, and M.V.B. Rao. Chemical Papers, 2018. 72(2): p. 457-468. ISI[000423584300020].
[WOS]. TB_02_2018.
3. Synthesis and in Vitro Evaluation of Substituted 3-Cinnamoyl-4-hydroxy-pyran-2-one (CHP) in Pursuit of New Potential Antituberculosis Agents. Bhat, Z.S., H.U. Lah, M.A. Rather, M. Maqbool, T. Ara, Z. Ahmad, and S.K. Yousuf. MedChemComm, 2018. 9(1): p. 165-172. ISI[000423465800017].
[WOS]. TB_02_2018.
4. 7-Oxa-4-thia-1-aza-bicyclo[3.2.1]octane 4,4-dioxides: Mechanochemical Synthesis by Tandem Michael Addition-1,3-Dipolar Cycloaddition of Aldoximes and Evaluation of Antibacterial Activities. Bhutia, Z.T., A. Das, M. Biswas, A. Chatterjee, and M. Banerjee. European Journal of Organic Chemistry, 2018. 2018(4): p. 506-514. ISI[000423772600010].
[WOS]. TB_02_2018.
5. New Hydrazides Derivatives of Isoniazid against Mycobacterium tuberculosis: Higher Potency and Lower Hepatocytotoxicity. Castelo-Branco, F.S., E.C. de Lima, J.L.O. Domingos, A.C. Pinto, M.C.S. Lourenco, K.M. Gomes, M.M. Costa-Lima, C.F. Araujo-Lima, C.A.F. Aiub, I. Felzenszwalb, T. Costa, C. Penido, M.G. Henriques, and N. Boechat. European Journal of Medicinal Chemistry, 2018. 146: p. 529-540. PMID[29407978].
[PubMed]. TB_02_2018.
6. Analogues of Disulfides from Allium stipitatum Demonstrate Potent Anti-tubercular Activities through Drug Efflux Pump and Biofilm Inhibition. Danquah, C.A., E. Kakagianni, P. Khondkar, A. Maitra, M. Rahman, D. Evangelopoulos, T.D. McHugh, P. Stapleton, J. Malkinson, S. Bhakta, and S. Gibbons. Scientific Reports, 2018. 8(1150): 7pp. PMID[29348586]. PMCID[PMC5773482].
[PubMed]. TB_02_2018.
7. In Vitro Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin.Dijkstra, J.A., T. van der Laan, O.W. Akkerman, M.S. Bolhuis, W.C.M. de Lange, J.G.W. Kosterink, T.S. van der Werf, J.W.C. Alffenaar, and D. van Soolingen. Antimicrobial Agents and Chemotherapy, 2018. 62(3): p. e01724-01717. PMID[29311078].
[PubMed]. TB_02_2018.
8. Evaluation of Antimycobacterial Activity of Higenamine Using Galleria mellonella as an in Vivo Infection Model.Erasto, P., J. Omolo, R. Sunguruma, J.J. Munissi, V. Wiketye, C. de Konig, and A.F. Ahmed. Natural Products and Bioprospecting, 2018. 8(1): p. 63-69. PMID[29357092]. PMCID[PMC5803147].
[PubMed]. TB_02_2018.
9. Anthranilate phosphoribosyltransferase: Binding Determinants for 5 '-Phospho-alpha-D-ribosyl-1 '-pyrophosphate (PRPP) and the Implications for Inhibitor Design.Evans, G.L., D.P. Furkert, N. Abermil, P. Kundu, K.M. de Lange, E.J. Parker, M.A. Brimble, E.N. Baker, and J.S. Lott. Biochimica et Biophysica Acta-Proteins and Proteomics, 2018. 1866(2): p. 264-274. PMID[28844746].
[PubMed]. TB_02_2018.
10. Fluoroquinolone Derivatives and Their Anti-tubercular Activities. Fan, Y.L., J.B. Wu, X.W. Cheng, F.Z. Zhang, and L.S. Feng. European Journal of Medicinal Chemistry, 2018. 146: p. 554-563. PMID[29407980].
[PubMed]. TB_02_2018.
11. Design, Synthesis, and Pharmacological Evaluation of Fluorinated azoles as Anti-tubercular Agents. Gholap, S., M. Tambe, L. Nawale, D. Sarkar, J. Sangshetti, and M. Damale. Archiv der Pharmazie, 2018. 351(2): p. e1700294. PMID[29292534].
[PubMed]. TB_02_2018.
12. Total Synthesis of Ecumicin.Hawkins, P.M.E., A.M. Giltrap, G. Nagalingam, W.J. Britton, and R.J. Payne. Organic Letters, 2018. 20(4): p. 1019-1022. PMID[29412668].
[PubMed]. TB_02_2018.
13. Design, Synthesis and in Vitro Anti-mycobacterial Activity of Propylene-1H-1,2,3-triazole-4-methylene-tethered Isatin-Moxifloxacin Hybrids. Hu, Y.Q., J. Fan, and X.F. Song. Journal of Heterocyclic Chemistry, 2018. 55(1): p. 246-250. ISI[000422654400027].
[WOS]. TB_02_2018.
14. Design, Synthesis, and in Vitro Anti-mycobacterial Evaluation 1H-1,2,3-Triazole-tethered Ciprofloxacin and Isatin Conjugates. Hu, Y.Q., L.D. Meng, M. Qiang, and X.F. Song. Journal of Heterocyclic Chemistry, 2017. 54(6): p. 3725-3729. ISI[000422654000088].
[WOS]. TB_02_2018.
15. Design, Synthesis, and in Vitro Antimycobacterial Activity of Propylene-tethered Isatin Dimmers. Hu, Y.Q., X.F. Song, and J. Fan. Journal of Heterocyclic Chemistry, 2018. 55(1): p. 265-268. ISI[000422654400030].
[WOS]. TB_02_2018.
16. Design, Synthesis and in Vitro Antimycobacterial Activities of Isatin-1,2,3-triazole-Moxifloxacin Hybrids.Hu, Y.Q., Z. Xu, M. Qiang, and Z.S. Lv. Journal of Heterocyclic Chemistry, 2018. 55(1): p. 187-191. ISI[000422654400020].
[WOS]. TB_02_2018.
17. Novel Pyrimidines as Antitubercular Agents. Inoyama, D., S.D. Paget, R. Russo, S. Kandasamy, P. Kumar, E. Singleton, J. Occi, M. Tuckman, M.D. Zimmerman, H.P. Ho, A.L. Perryman, V. Dartois, N. Connell, and J.S. Freundlich. Antimicrobial Agents and Chemotherapy, 2018. 62(3): p. e02063-02017. PMID[29311070].
[PubMed]. TB_02_2018.
18. Design, Synthesis, Molecular Modeling, and ADMET Studies of Some Pyrazoline Derivatives as Shikimate kinase Inhibitors. James, J.P., K.I. Bhat, U.A. More, and S.D. Joshi. Medicinal Chemistry Research, 2018. 27(2): p. 546-559. ISI[000424646600019].
[WOS]. TB_02_2018.
19. Naphthofuroquinone Derivatives Show Strong Antimycobacterial Activities against Drug-resistant Mycobacteria.Jang, W.S., Y.S. Choi, S. Kim, M.A. Jyoti, H. Seo, J. Han, Y.S. Kim, J. Lyu, K.W. Nam, B.E. Lee, K.I. Lee, and H.Y. Song. Journal of Chemotherapy, 2017. 29(6): p. 338-343. PMID[28281912].
[PubMed]. TB_02_2018.
20. Design, Synthesis and in Vitro Anti-microbial Evaluation of Ethylene/Propylene-1H-1,2,3-triazole-4-methylene-tethered Isatin-Coumarin Hybrids.Jin, X.H., Y. Xu, X.H. Yang, X.L. Chen, M.H. Wu, J.G. Guan, and L.S. Feng. Current Topics in Medicinal Chemistry, 2017. 17(29): p. 3213-3218. PMID[29243578].
[PubMed]. TB_02_2018.
21. Synthesis and Antitubercular Activity of Novel 1,3,4-Oxadiazole and 1,3,4-Thiadiazole Derivatives.Joshi, S.D., S. Tiwari, and V.H. Kulkarni. Indian Journal of Heterocyclic Chemistry, 2017. 27(4): p. 417-421. ISI[000423975800015].
[WOS]. TB_02_2018.
22. Synthesis and Mechanistic Investigation of Iron(II) Complexes of Isoniazid and Derivatives as a Redox-Mediated Activation Strategy for Anti-Tuberculosis Therapy. Laborde, J., C. Deraeve, F.G. de Mesquita Vieira, A. Sournia-Saquet, L. Rechignat, A.D. Villela, B.L. Abbadi, F.S. Macchi, K. Pissinate, C.V. Bizarro, P. Machado, L.A. Basso, G. Pratviel, L.G. de Franca Lopes, E.H.S. Sousa, and V. Bernardes-Genisson. Journal of Inorganic Biochemistry, 2018. 179: p. 71-81. PMID[29175704].
[PubMed]. TB_02_2018.
23. First Identification of Marine Diatoms with Anti-tuberculosis Activity. Lauritano, C., J. Martin, M. de la Cruz, F. Reyes, G. Romano, and A. Ianora. Scientific Reports, 2018. 8(2284): 10pp. PMID[29396507]. PMCID[PMC5797112].
[PubMed]. TB_02_2018.
24. Physicochemical, Pharmacokinetic, Efficacy and Toxicity Profiling of a Potential Nitrofuranyl methyl piperazine Derivative IIIM-MCD-211 for Oral Tuberculosis Therapy via in-Silico-in-Vitro-in-Vivo Approach. Magotra, A., A. Sharma, S. Singh, P.K. Ojha, S. Kumar, N. Bokolia, P. Wazir, S. Sharma, I.A. Khan, P.P. Singh, R.A. Vishwakarma, G. Singh, and U. Nandi. Pulmonary Pharmacology & Therapeutics, 2018. 48: p. 151-160. PMID[29174840].
[PubMed]. TB_02_2018.
25. Identification and Development of Benzoxazole Derivatives as Novel Bacterial Glutamate racemase Inhibitors.Malapati, P., V.S. Krishna, R. Nallangi, R.R. Srilakshmi, and D. Sriram. European Journal of Medicinal Chemistry, 2018. 145: p. 23-34. PMID[29310027].
[PubMed]. TB_02_2018.
26. Synthesis of Coumarin-Theophylline Hybrids as a New Class of Anti-tubercular and Anti-microbial Agents. Mangasuli, S.N., K.M. Hosamani, H.C. Devarajegowda, M.M. Kurjogi, and S.D. Joshi. European Journal of Medicinal Chemistry, 2018. 146: p. 747-756. PMID[29407993].
[PubMed]. TB_02_2018.
27. Design, Synthesis, SAR and Biological Investigation of 3-(Carboxymethyl)rhodanine and Aminothiazole Inhibitors of Mycobacterium Tuberculosis Zmp1. Mori, M., D. Deodato, M. Kasula, D.M. Ferraris, A. Sanna, A. De Logu, M. Rizzi, and M. Botta. Bioorganic & Medicinal Chemistry Letters, 2018. 28(4): p. 637-641. PMID[29395975].
[PubMed]. TB_02_2018.
28. Evaluation of Heteroatom-rich Derivatives as Antitubercular Agents with InhA Inhibition Properties.Moulkrere, B.R., B.S. Orena, G. Mori, N. Saffon-Merceron, F. Rodriguez, C. Lherbet, N. Belkheiri, M. Amari, P. Hoffmann, and M. Fodili. Medicinal Chemistry Research, 2018. 27(1): p. 308-320. ISI[000419972400027].
[WOS]. TB_02_2018.
29. Combinatorial Design and Virtual Screening of Potent Anti-tubercular Fluoroquinolone and Isothiazoloquinolone Compounds Utilizing QSAR and Pharmacophore Modelling. Nandi, S., S. Ahmed, and A.K. Saxena. SAR and QSAR in Environmental Research, 2018. 29(2): p. 151-170. PMID[29347843].
[PubMed]. TB_02_2018.
30. Whole-cell Screen of Fragment Library Identifies Gut Microbiota Metabolite Indole propionic acid as Antitubercular.Negatu, D.A., J.J.J. Liu, M. Zimmerman, F. Kaya, V. Dartois, C.C. Aldrich, M. Gengenbacher, and T. Dick. Antimicrobial Agents and Chemotherapy, 2018. 62(3): p. e01571-01517. PMID[29229639].
[PubMed]. TB_02_2018.
31. P2O5 Mediated an Efficient Synthesis and Biological Evaluation of Heterocyclic-fused pyrimidine Derivatives as an Antitubercular Agent. Patil, K.T., P.P. Warekar, P.T. Patil, S.S. Undare, G.B. Kolekar, and P.V. Anbhule. Journal of Heterocyclic Chemistry, 2018. 55(1): p. 154-160. ISI[000422654400015].
[WOS]. TB_02_2018.
32. Novel Indole and Triazole Based Hybrid Molecules Exhibit Potent Anti-adipogenic and Antidyslipidemic Activity by Activating Wnt3a/beta-Catenin Pathway. Rajan, S., S. Puri, D. Kumar, M.H. Babu, K. Shankar, S. Varshney, A. Srivastava, A. Gupta, M.S. Reddy, and A.N. Gaikwad. European Journal of Medicinal Chemistry, 2018. 143: p. 1345-1360. PMID[29153558].
[PubMed]. TB_02_2018.
33. Synthesis of New 7-Chloro-4-phenoxyquinoline Analogues as Potential Antitubercular Agents. Salve, P.S. and S.G. Alegaon. Medicinal Chemistry Research, 2018. 27(1): p. 1-14. ISI[000419972400001].
[WOS]. TB_02_2018.
34. Design, Synthesis, and Evaluation of New alpha-Aminonitrile-based benzimidazole Biomolecules as Potent Antimicrobial and Antitubercular Agents. Shaikh, I.N., K.M. Hosamani, and M.M. Kurjogi. Archiv der Pharmazie, 2018. 351(2): p. e1700205. PMID[29356105].
[PubMed]. TB_02_2018.
35. Synthesis and Biological Evaluation of New 2-Aryl-4-((4-aryl-1H-1,2,3-triazol-1-yl)methyl)thiazole Derivatives. Shinde, V., P. Mahulikar, P.C. Mhaske, L. Nawale, and D. Sarkar. Research on Chemical Intermediates, 2018. 44(2): p. 1247-1260. ISI[000422905700031].
[WOS]. TB_02_2018.
36. Synthesis and Biological Evaluation New Imidazo[2,1-b]thiazoles. Syed, M.A., P.R. Yiragamreddy, and K.B. Chandrasekhar. Indian Journal of Heterocyclic Chemistry, 2017. 27(4): p. 329-338. ISI[000423975800002].
[WOS]. TB_02_2018.
37. Synthesis and in Vitro Investigation of Halogenated 1,3-bis(4-Nitrophenyl)triazenide Salts as Antitubercular Compounds. Torfs, E., J. Vajs, M.B. de Macedo, F. Cools, B. Vanhoutte, Y. Gorbanev, A. Bogaerts, L. Verschaeve, G. Caljon, L. Maes, P. Delputte, P. Cos, J. Kosmrlj, and D. Cappoen. Chemical Biology & Drug Design, 2018. 91(2): p. 631-640. PMID[28845550].
[PubMed]. TB_02_2018.
38. Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-line Tuberculosis Drugs Isoniazid and Rifampin in Mice. Vilcheze, C., J. Kim, and W.R. Jacobs, Jr. Antimicrobial Agents and Chemotherapy, 2018. 62(3): p. e02165-02117. PMID[29298757].
[PubMed]. TB_02_2018.
39. Cyclipostins and Cyclophostin Analogs Inhibit the Antigen 85c from Mycobacterium Tuberculosis Both in Vitro and in Vivo. Viljoen, A., M. Richard, P.C. Nguyen, P. Fourquet, L. Camoin, R.R. Paudal, G.R. Gnawali, C.D. Spilling, J.F. Cavalier, S. Canaan, M. Blaise, and L. Kremer. The Journal of Biological Chemistry, 2018. 293(8): p. 2755-2769. PMID[29301937]. PMCID[PMC5827452].
[PubMed]. TB_02_2018.
40. Ciprofloxacin-Isatin-1H-1,2,3-triazole Hybrids: Design, Synthesis, and in Vitro Anti-tubercular Activity against M.tuberculosis.Xu, Z., Z.S. Lv, X.F. Song, and M. Qiang. Journal of Heterocyclic Chemistry, 2018. 55(1): p. 97-102. ISI[000422654400008].
[WOS]. TB_02_2018.
41. Design, Synthesis, and in Vitro Anti-mycobacterial Evaluation of Propylene-1H-1,2,3-triazole-4-methylene-tethered (Thio)Semicarbazone-Isatin-Moxifloxacin Hybrids.Xu, Z., X.F. Song, J. Fan, and Z.S. Lv. Journal of Heterocyclic Chemistry, 2018. 55(1): p. 77-82. ISI[000422654400005].
[WOS]. TB_02_2018.
42. Design, Synthesis and in Vitro Anti-mycobacterial Activities of 8-OMe Ciprofloxacin-1H-1,2,3-triazole-Isatin-(Thio) Semicarbazide/oxime Hybrids. Xu, Z., X.F. Song, Y.Q. Hu, M. Qiang, and Z.S. Lv. Journal of Heterocyclic Chemistry, 2018. 55(1): p. 192-198. ISI[000422654400021].
[WOS]. TB_02_2018.
43. 1H-1,2,3-Triazole-tethered 8-OMe Ciprofloxacin and Isatin Hybrids: Design, Synthesis and in Vitro Anti-mycobacterial Activities. Xu, Z., X.F. Song, M. Qiang, and Z.S. Lv. Journal of Heterocyclic Chemistry, 2017. 54(6): p. 3735-3741. ISI[000422654000090].
[WOS]. TB_02_2018.
Patent Citations
This month, no relevant Mycobacterium patents were identified.